Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Thorac Oncol. 2009 Apr;4(4):444-7. doi: 10.1097/JTO.0b013e31819d6f91.

MET pathway as a therapeutic target.

Author information

  • 1Section of Hematology/Oncology, Department of Medicine, University of Chicago Medical Center, Chicago, Illinois 60637, USA. rsalgia@medicine.bsd.uchicago.edu

Abstract

Dysregulation of mesenchymal-epithelial transition factor receptor tyrosine kinase pathway leads to cell proliferation, protection from apoptosis, angiogenesis, invasion, and metastasis. It can be dysregulated through overexpression, constitutive activation, gene amplification, ligand-dependent activation or mutation. New drugs targeting various mesenchymal-epithelial transition factor pathways are being investigated with promising results.

PMID:
19333071
[PubMed - indexed for MEDLINE]
PMCID:
PMC2664527
Free PMC Article

Images from this publication.See all images (1)Free text

Figure 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins Icon for PubMed Central
    Loading ...
    Write to the Help Desk